EDP Renovaveis (0ML1)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 12.01 |
|---|---|
| 52-week range | 11.09 – 14.64 |
| Return, 1 month / 3 months | −9.2% / −16.1% |
| Return, 1 year / 3 years | −8.8% / +46.4% |
| Trend | Below its 200-day average |
| RSI (14) | 37 |
| Volatility (1 year) | 29.0% |
| Worst drawdown (1 year) | -17.6% |
| Average daily value traded | 1.67M EUR |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
EDP Renováveis develops, builds and operates renewable power plants, chiefly onshore wind farms and solar photovoltaic installations, with additional activity in offshore wind. Its customers are electricity utilities, grid operators and corporate buyers of clean power, and its projects are spread across Europe, North America, South America and Asia-Pacific. The company is the renewables subsidiary of the Portuguese energy group EDP and is based in Madrid, Spain.
On this site EDP Renovaveis appears as a stock on the London Exchange (UK), code 0ML1, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
EDP Renovaveis (0ML1) trades on the London Exchange in UK. It last closed at EUR 12.01 on 22 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 2,264 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 8.8% and over the last three months it fell 16.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 37 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.2% | ||
| From 52-week high | -17.9% | ||
| Momentum | 30 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -16.1% | ||
| 6-month return | -11.5% | ||
| 12-month return, skipping the last month | 0.5% | ||
| Stability (higher is calmer) | 72 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.6% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.67M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 29 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −1.2% |
|---|---|
| 1 month | −9.2% |
| 3 months | −16.1% |
| 6 months | −11.5% |
| 1 year | −8.8% |
| 3 years | +46.4% |
| 5 years | −12.8% |
Signals
| 50-day / 200-day average | 12.94 / 13.37 |
|---|---|
| Golden / death cross (60 days) | Death, 15 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.49 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 May 2026 | EUR 0.1240 |
| 16 Apr 2025 | EUR 0.0840 |
| 2 May 2024 | EUR 0.2009 |
| 29 Apr 2024 | EUR 4.9219 |
| 9 May 2023 | EUR 0.2650 |
| 27 Apr 2022 | EUR 0.0900 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.